{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:58:41Z","timestamp":1774364321355,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.braindev.2022.11.002","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T16:59:51Z","timestamp":1669741191000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study"],"prefix":"10.1016","volume":"45","author":[{"given":"Yuko","family":"Shimizu-Motohashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3170-5217","authenticated-orcid":false,"given":"Emiko","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-1836","authenticated-orcid":false,"given":"Hiroyuki","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-2912","authenticated-orcid":false,"given":"Masayuki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-1417","authenticated-orcid":false,"given":"Hirofumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2022.11.002_b0005","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0010","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2022.11.002_b0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2022.11.002_b0020","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2022.11.002_b0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.braindev.2022.11.002_b0030","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.braindev.2022.11.002_b0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2022.11.002_b0040","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mus.27384","article-title":"Different trajectories in upper limb and gross motor function in spinal muscular atrophy","volume":"64","author":"Coratti","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2022.11.002_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2022.11.002_b0065","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","article-title":"Nusinersen: A Review in 5q Spinal Muscular Atrophy","volume":"35","author":"Hoy","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.braindev.2022.11.002_b0070","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2022.11.002_b0075","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2022.11.002_b0080","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0085","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00415-019-09646-w","article-title":"MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients","volume":"267","author":"Brogna","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0090","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2022.11.002_b0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.nmd.2005.01.004","article-title":"Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy","volume":"15","author":"Mercuri","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2022.11.002_b0105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7\u20139 November 2014, Heemskerk","volume":"25","author":"Finkel","year":"2015","journal-title":"The Netherlands Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2022.11.002_b0110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejpn.2021.02.009","article-title":"Pediatric SMA patients with complex spinal anatomy: Implementation and evaluation of a decision-tree algorithm for administration of nusinersen","volume":"31","author":"Carrera-Garc\u00eda","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13023-021-01903-4","article-title":"Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2022.11.002_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18179134","article-title":"Motor Function of Children with SMA1 and SMA2 Depends on the Neck and Trunk Muscle Strength, Deformation of the Spine, and the Range of Motion in the Limb Joints","volume":"18","author":"St\u0119pie\u0144","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.braindev.2022.11.002_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Osredkar","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0130","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2022.11.002_b0135","first-page":"Cd006282","article-title":"Drug treatment for spinal muscular atrophy types II and III","volume":"1","author":"Wadman","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.braindev.2022.11.002_b0140","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical Variability in Spinal Muscular Atrophy Type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2022.11.002_b0145","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","article-title":"Age and baseline values predict 12 and 24-month functional changes in type 2 SMA","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2022.11.002_b0150","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.braindev.2019.06.008","article-title":"Automatic calculation of Mercuri grades from CT and MR muscle images","volume":"41","author":"Nakayama","year":"2019","journal-title":"Brain and Development"},{"key":"10.1016\/j.braindev.2022.11.002_b0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.braindev.2022.11.002_b0160","doi-asserted-by":"crossref","first-page":"e4473","DOI":"10.1002\/nbm.4473","article-title":"Quantification of disease progression in spinal muscular atrophy with muscle MRI-a pilot study","volume":"34","author":"Otto","year":"2021","journal-title":"NMR Biomed"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760422001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760422001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:51:16Z","timestamp":1759953076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760422001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0387760422001917"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2022.11.002","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2022.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology.","name":"copyright","label":"Copyright"}]}}